UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing

0001811884-21-000016.txt : 20211112 0001811884-21-000016.hdr.sgml : 20211112 20211112104520 ACCESSION NUMBER: 0001811884-21-000016 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 211401289 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 10-Q 1 utmd-20210930.htm UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-12575

UTAH MEDICAL PRODUCTS INC

(Exact name of Registrant as specified in its charter)

Utah	87-0342734
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

7043 South 300 West

Midvale, Utah 84047

(Address of principal executive offices) (Zip Code)

(801) 566-1200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol:	Name of each exchange on which registered:
Common stock, $0.01 par value	UTMD	NASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of November 11, 2021: 3,650,929.

UTAH MEDICAL PRODUCTS, INC.

INDEX TO FORM 10-Q

		PAGE
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements

	Consolidated Condensed Balance Sheets as of September 30, 2021 and December 31, 2020	1

	Consolidated Condensed Statements of Income for the three and nine months ended September 30, 2021 and September 30, 2020	2

	Consolidated Condensed Statements of Cash Flows for the nine months ended September 30, 2021 and September 30, 2020	3

	Consolidated Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and September 30, 2020	4

	Notes to Consolidated Condensed Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	7

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	16

Item 4.	Controls and Procedures	16

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	17

Item 1A.	Risk Factors	17

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

Item 6.	Exhibits	18

SIGNATURES		19

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
SEPTEMBER 30, 2021 AND DECEMBER 31, 2020
(in thousands)
	(unaudited)	(audited)
	SEPTEMBER 30, 2021	DECEMBER 31, 2020
ASSETS
Current assets:
Cash & investments	$ 64,321	$ 51,590
Accounts & other receivables, net	4,853	4,104
Inventories	6,299	6,222
Other current assets	373	346
Total current assets	75,846	62,262
Property and equipment, net	10,547	10,949
Operating lease – right-of-use assets, net	384	377
Goodwill	14,064	14,164
Other intangible assets	55,701	56,159
Other intangible assets - accumulated amortization	(36,790)	(32,166)
Other intangible assets, net	18,911	23,993
Total assets	$ 119,752	$ 111,745

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$ 1,026	$ 788
Accrued expenses	3,989	3,003
Total current liabilities	5,015	3,791
Deferred tax liability – Femcare IIA	1,810	2,151
Other long term liabilities	2,196	1,995
Operating lease liability	343	335
Deferred income taxes	408	651
Total liabilities	9,772	8,923

Stockholders' equity:
Common stock - $0.01 par value; authorized - 50,000 shares; issued - September 30, 2021, 3,649 shares and December 31, 2020, 3,643 shares	36	36
Accumulated other comprehensive income (loss)	(9,068)	(8,281)
Additional paid-in capital	520	115
Retained earnings	118,492	110,952
Total stockholders' equity	109,980	102,822

Total liabilities and stockholders' equity	$ 119,752	$ 111,745

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND SEPTEMBER 30, 2020
(in thousands, except per share amounts - unaudited)
	Three Months Ended		Nine Months Ended
	September 30, 2021	September 30, 2020	September 30, 2021	September 30, 2020

Sales, net	$ 12,572	$ 10,479	$ 36,140	$ 30,168

Cost of goods sold	4,499	3,982	13,336	11,885
Gross profit	8,073	6,497	22,804	18,283

Operating expense
Selling, general and administrative	2,848	2,785	8,669	8,480
Research & development	127	125	385	375
Total operating expenses	2,975	2,910	9,054	8,855
Operating income	5,098	3,587	13,750	9,428

Other income	59	1	130	125
Income before provision for income taxes	5,157	3,588	13,880	9,553

Provision for income taxes	951	655	3,224	2,167
Net income	$ 4,206	$ 2,933	$ 10,656	$ 7,386

Earnings per common share (basic)	$ 1.15	$ 0.81	$ 2.92	$ 2.02

Earnings per common share (diluted)	$ 1.15	$ 0.80	$ 2.91	$ 2.01

Shares outstanding - basic	3,647	3,642	3,645	3,664

Shares outstanding - diluted	3,658	3,653	3,656	3,678

Other comprehensive income (loss):
Foreign currency translation net of taxes of $0 in all periods	$ (782)	$ 1,511	$ (787)	$ (416)
Total comprehensive income	$ 3,424	$ 4,444	$ 9,869	$ 6,970

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND SEPTEMBER 30, 2020
(in thousands - unaudited)
	Nine Months Ended September 30,
	2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 10,656	$ 7,386
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	483	495
Amortization	4,996	4,875
Provision for (recovery of) losses on accounts receivable	20	(4)
Amortization of right-of-use assets	32	29
(Gain) loss on disposal of assets	-	1
Deferred income taxes	(160)	(20)
Stock-based compensation expense	123	121
Tax benefit attributable to exercise of stock options	11	7
Changes in operating assets and liabilities:
Accounts receivable and other receivables	(802)	442
Inventories	(161)	757
Prepaid expenses and other current assets	(35)	58
Accounts payable	242	(439)
Accrued expenses	811	651
Total adjustments	5,560	6,973
Net cash provided by operating activities	16,216	14,359

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment	(299)	(806)
Net cash used in investing activities	(299)	(806)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	281	282
Common stock purchased and retired	-	(6,977)
Payment of dividends	(3,116)	(3,097)
Net cash used in financing activities	(2,835)	(9,792)

Effect of exchange rate changes on cash	(351)	(254)
Net increase in cash and cash equivalents	12,731	3,507
Cash at beginning of period	51,590	42,787
Cash at end of period	$ 64,321	$ 46,294

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for income taxes	$ 3,094	$ 2,153
Cash paid during the period for interest	-	-

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY FOR THE
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND SEPTEMBER 30, 2020
(In thousands - unaudited)
				Accumulated
			Additional	Other		Total
	Common Stock		Paid-in	Comprehensive	Retained	Stockholders'
	Shares	Amount	Capital	Income	Earnings	Equity
Balance at June 30, 2021	3,646	$ 36	$ 289	$ (8,286)	$ 115,326	$ 107,365
Shares issued upon exercise of employee stock options for cash	3	-	189	-	-	189
Stock option compensation expense	-	-	41	-	-	41
Foreign currency translation adjustment	-	-	-	(782)	-	(782)
Common stock dividends	-	-	-	-	(1,040)	(1,040)
Net income	-	-	-	-	4,206	4,206
Balance at September 30, 2021	3,649	$ 36	$ 520	$ (9,068)	$ 118,492	$ 109,980

Balance at December 31, 2020	3,643	$ 36	$ 115	$ (8,281)	$ 110,951	$ 102,822
Shares issued upon exercise of employee stock options for cash	6	-	281	-	-	281
Stock option compensation expense	-	-	123	-	-	123
Foreign currency translation adjustment	-	-	-	(787)	-	(787)
Common stock dividends	-	-	-	-	(3,116)	(3,116)
Net income	-	-	-	-	10,656	10,656
Balance at September 30, 2021	3,649	$ 36	$ 520	$ (9,068)	$ 118,492	$ 109,980

Balance at June 30, 2020	3,643	$ 36	$ 80	$ (11,710)	$ 106,881	$ 95,288
Shares issued upon exercise of employee stock options for cash	4	-	202	-	-	202
Stock option compensation expense	-	-	49	-	-	49
Common stock purchased and retired	(7)	-	(332)	-	(219)	(551)
Foreign currency translation adjustment	-	-	-	1,511	-	1,511
Common stock dividends	-	-	-	-	(1,018)	(1,018)
Net income	-	-	-	-	2,933	2,933
Balance at September 30, 2020	3,640	$ 36	$ -	$ (10,199)	$ 108,578	$ 98,415

Balance at December 31, 2019	3,722	$ 37	$ 18	$ (9,783)	$ 110,820	$ 101,092
Shares issued upon exercise of employee stock options for cash	6	-	282	-	-	282
Stock option compensation expense	-	-	121	-	-	121
Common stock purchased and retired	(87)	(1)	(421)	-	(6,555)	(6,976)
Foreign currency translation adjustment	-	-	-	(416)	-	(416)
Common stock dividends	-	-	-	-	(3,074)	(3,074)
Net income	-	-	-	-	7,386	7,386
Balance at September 30, 2020	3,640	$ 36	$ -	$ (10,199)	$ 108,578	$ 98,415

see notes to consolidated condensed financial statements

Table of Contents

UTAH MEDICAL PRODUCTS, INC.

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(unaudited)

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2020. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards.

The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

(3) Inventories at September 30, 2021, and December 31, 2020, consisted of the following:

		September 30, 2021		December 31, 2020
Finished goods	$	1,436	$	1,363
Work-in-process		1,459		1,375
Raw materials		3,404		3,484
Total	$	6,299	$	6,222

(4) Stock-Based Compensation. At September 30, 2021, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended September 30, 2021, and 2020, the Company recognized $41 and $49, respectively, in stock based compensation cost. In the nine months ended September 30, 2021, and 2020, the Company recognized $123 and $121, respectively, in stock based compensation cost.

(5) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2020, or September 30, 2021.

(6) Global 3Q 2021 revenues (USD) by product category:

		Domestic		Outside US		Total
Obstetrics	$	1,014	$	232	$	1,246
Gynecology/Electrosurgery/Urology		2,743		2,815		5,558
Neonatal		1,336		312		1,648
Blood Pressure Monitoring and Accessories		2,656		1,464		4,120
Total	$	7,749	$	4,823	$	12,572

Global 9M 2021 revenues (USD) by product category:

		Domestic		Outside US		Total
Obstetrics	$	2,864	$	559	$	3,423
Gynecology/Electrosurgery/Urology		8,229		8,130		16,359
Neonatal		3,813		1,064		4,877
Blood Pressure Monitoring and Accessories		7,649		3,832		11,481
Total	$	22,555	$	13,585	$	36,140

Table of Contents

(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over a remaining 2.08 year life as of September 30, 2021 of the prior CSI distribution agreement with Femcare.

(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3rd quarter 2021.

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:

(in thousands)	Three months ended		Nine months ended
	September 30,		September 30,
	2021	2020	2021	2020
Numerator
Net income	4,206	2,933	10,656	7,386

Denominator
Weighted average shares, basic	3,647	3,642	3,645	3,664
Dilutive effect of stock options	11	11	11	14
Diluted shares	3,658	3,653	3,656	3,678

Earnings per share, basic	1.15	0.81	2.92	2.02
Earnings per share, diluted	1.15	0.80	2.91	2.01

(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General

Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. The Company’s Form 10-K Annual Report for the year ended December 31, 2020, provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. Because of government mandates for medical facilities to not perform certain “elective” procedures in order to theoretically preserve capacity for treating COVID-19 infected patients in 2020, the comparison of 2021 performance with the prior year’s same periods of time represents an unusual change. As a result, UTMD provides an additional summary comparison of 2021 results to the same periods of time in 2019, prior to the pandemic. Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole.

Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. Currencies in this report are denoted as $ or USD = U.S. Dollars; A$ or AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Analysis of Results of Operations

a)Overview

Income statement results in 3Q and 9M 2021 compared to the same periods of 2020 were as follows:

	3Q 2021	3Q 2020	change	9M 2021	9M 2020	change
Net Sales	$ 12,572	$ 10,479	20.0%	$ 36,140	$ 30,168	19.8%
Gross Profit	8,073	6,497	24.3%	22,804	18,283	24.7%
Operating Income	5,098	3,588	42.1%	13,750	9,428	45.8%
Income Before Tax	5,157	3,588	43.7%	13,880	9,553	45.3%
Net Income (NI)	4,206	2,933	43.4%	10,656	7,386	44.3%
Earnings per Diluted Share (EPS)	1.150	0.803	43.2%	2.915	2.008	45.2%

Income statement results in 3Q and 9M 2021 compared to the same periods of 2019 were as follows:

	3Q 2021	3Q 2019	change	9M 2021	9M 2019	change
Net Sales	$ 12,572	$ 12,494	0.6%	$ 36,140	$ 35,073	3.0%
Gross Profit	8,073	7,379	9.4%	22,804	21,652	5.3%
Operating Income	5,098	4,371	16.6%	13,750	12,954	6.2%
Income Before Tax	5,157	4,448	16.0%	13,880	13,150	5.6%
Net Income (NI)	4,206	3,705	13.5%	10,656	10,369	2.8%
Earnings per Diluted Share (EPS)	1.150	0.991	16.0%	2.915	2.774	5.1%

UTMD profit margins in 3Q 2021 and 9M 2021 compared to the same periods in the prior two years follow:

	3Q 2021	3Q 2020	3Q 2019	9M 2021	9M 2020	9M 2019
	(Jul – Sep)	(Jul – Sep)	(Jul – Sep)	(Jan – Sep)	(Jan – Sep)	(Jan – Sep)
Gross Profit Margin: (gross profit/ sales)	64.2%	62.0%	59.1%	63.1%	60.6%	61.7%
Operating Income Margin: (operating income/ sales)	40.6%	34.2%	35.0%	38.0%	31.3%	36.9%
Net Income Margin: (profit after taxes/ sales)	33.5%	28.0%	29.7%	29.5%	24.5%	29.6%

Gross Profit in 2021 periods increased more than sales primarily as a result of greater absorption of fixed manufacturing overhead expenses. Because UTMD believed that lower 2020 sales were transitory, and that it could remain profitable even at the lower sales levels experienced during the pandemic, 2021 results benefited from having the resources the Company needed in 2021 to support the higher sales activity.

Operating Income increased substantially more than the Gross Profit increase in both 2021 periods because UTMD’s non-cash identifiable intangible asset (IIA) amortization expense included in operating expenses was relatively fixed (except for foreign exchange rate difference on GBP), and therefore enjoyed better absorption from higher sales. IIA amortization expense was 13.1% of 3Q 2021 sales compared to 15.5% of 3Q 2020 sales, and 13.8% of 9M 2021 sales compared to 16.0% of 9M 2020 sales.

Table of Contents

Income before tax (EBT) increased slightly differently from the increases in operating income as a result of small differences in period-to-period non-operating income, as explained later in this report. Similarly, Net Income increased slightly differently from the increase in EBT as a result of the sovereignty mix of taxable profits in 2021 compared to 2020.

UTMD’s FX rates for balance sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of September 2021 and the end of September 2020 follow:

	Sep 30, 2021	Sep 30, 2020	Change
GBP	1.347	1.292	+4.3%
EUR	1.158	1.172	(1.3%)
AUD	0.723	0.716	+0.9%
CAD	0.789	0.751	+5.1%

UTMD’s September 30, 2021 Balance Sheet remained strong with an absence of debt. UTMD’s consolidated cash balances gained $12.7 million from the end of 2020. September 30, 2021 inventories were essentially the same as one year ago. September 30, 2021 trade receivables were up just 13% despite the 20% increase in sales. The USD net book value of fixed assets in the U.S., as well as outside the U.S. (OUS), remained about the same as of September 30, 2021 from a year earlier. Over the one year period of time, the net intangible asset balance declined $5.8 million, about 15%. Ending cash and investments were $64.3 million on September 30, 2021 compared to $51.6 million on December 31, 2020, after paying $3.1 million in cash dividends to stockholders during 9M 2021. September 30, 2021 stockholders’ equity was up $7.2 million from December 31, 2020.

b)Revenues

Terms of sale are established in advance of UTMD’s acceptance of customer orders. In the U.S., Ireland, UK, France, Canada and Australia, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD’s Standard Terms and Conditions (T&C) of Sale. About 14% of UTMD’s domestic end user sales, excluding Filshie device sales, go through third party med/surg distributors which contract separately with clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility. UTMD’s T&C of Sale to end user facilities are substantially the same in the U.S., Ireland, UK, France, Canada and Australia..

UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer’s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD’s disclosure that the selling price is fixed prior to the acceptance of a specific customer order.

Total consolidated 3Q 2021 UTMD sales were $2,094 (20.0%) higher than in 3Q 2020. Constant currency sales were $2,006 (19.1%) higher. Total consolidated 9M 2021 UTMD sales were $5,972 (19.8%) higher than in 9M 2020. Constant currency sales in 9M 2021 were $5,303 (17.6%) higher than in 9M 2020.

In 3Q 2021 compared to 3Q 2020, U.S. domestic sales were 11% higher and OUS sales were 37% higher. In 9M 2021 compared to 9M 2020, U.S. domestic sales were 19% higher and OUS sales were 21% higher.

Domestic sales in 3Q 2021 were $7,749 compared to $6,950 in 3Q 2020. Domestic sales in 9M 2021 were $22,555 compared to $18,906 in 9M 2020. The components of domestic sales include 1) “direct sales” of UTMD’s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie Clip System (“Filshie device”) sales, 2) “OEM sales” of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) Filshie device sales direct to U.S. medical facilities starting in February 2019.

Domestic direct sales in 3Q 2021 excluding Filshie devices, representing 48% of total domestic sales, were $277 (+8%) higher than in 3Q 2020. Domestic direct sales in 9M 2021 excluding Filshie devices, also representing 48% of total domestic sales, were $1,229 (+13%) higher than in 9M 2020. OEM sales in 3Q 2021, representing 32% of total domestic sales, were $704 (+40%) higher than in 3Q 2020. OEM sales in 9M 2021, representing 31% of total domestic sales, were $2,350 (+50%) higher than in 9M 2020. Filshie device sales direct to U.S. domestic end-user facilities were $182 (10%) lower in 3Q 2021 compared to sales in 3Q 2020. Filshie device sales direct to U.S. domestic end-user facilities were $69 (+2%) higher in 9M 2021 compared to Filshie device sales in 9M 2020.

OUS sales in 3Q 2021 were $4,823 (+37%) compared to $3,528 in 3Q 2020. OUS sales in 9M 2021 were $13,585 (+21%) compared to $11,262 in 9M 2020.

Table of Contents

UTMD subsidiary direct domestic sales in Canada, Ireland, the United Kingdom, France and Australia are invoiced in foreign currencies. Foreign currency exchange (FX) rates for income statement purposes are transaction-weighted averages. The average rates from the applicable foreign currency to USD during 3Q 2021 and 9M 2021 compared to the same periods in 2020 follow:

	3Q 21	3Q 20	Change	9M 21	9M 20	Change
GBP	1.379	1.295	+6.5%	1.386	1.279	+8.3%
EUR	1.179	1.173	+0.6%	1.196	1.128	+6.0%
AUD	0.735	0.714	+2.9%	0.758	0.677	+12.0%
CAD	0.794	0.751	+5.7%	0.798	0.745	+7.2%

The volatility of FX rates for OUS sales when consolidated in USD terms continues to impact period-to-period relative financial results because of UTMD’s significant percentage of foreign currency sales. Foreign currency revenues in 3Q 2021 were increased by $88 as a result of a weaker USD compared to 3Q 2020. The difference in period-to-period FX rates increased revenues by $669 in 9M 2021. Foreign currency sales as a percentage of total sales were 26.7% of total sales in 3Q 2021 and 27.0% of total sales in 9M 2021. UTMD’s 3Q 2020 and 9M 2020 revenues invoiced in foreign currencies represented 21.0% and 22.0% of total consolidated USD sales respectively.

Foreign currency OUS sales were more affected by the pandemic in 2020 than USD sales. Foreign currency OUS sales in 3Q 2021 were $3,352, which was 70% of all OUS sales. In comparison, foreign currency OUS sales in 3Q 2020 were $2,205, which was 62% of all OUS sales. The foreign currency OUS sales in 9M 2021 were $9,766, which was 72% of all OUS sales. In comparison, foreign currency OUS sales in 9M 2020 were $6,653, which was 59% of all OUS sales.

UTMD segments sales into the following general product categories: gynecology/ electrosurgery, labor & delivery, neonatal, and miscellaneous including blood pressure monitoring kits and accessories as well as related OEM products.

In 3Q 2021 compared to 3Q 2020, worldwide gynecology/ electrosurgery and neonatal device sales were both up 10%, worldwide labor & delivery device sales were 3% lower, and worldwide blood pressure monitoring and related OEM product sales were up 55%. In 9M 2021 compared to 9M 2020, worldwide gynecology/ electrosurgery device sales were up 12%, worldwide labor & delivery device sales were up 2%, worldwide neonatal device sales were up 10% and worldwide blood pressure monitoring and related OEM product sales were up 48%. Medical facility procedures in L&D and the NICU during the 2020 pandemic did not decline as much as procedures utilizing devices in the gynecology/ electrosurgery category.

The following table provides USD sales amounts divided into general product categories for total sales and the subset of OUS sales:

Global 3Q 2021 revenues (USD) by product category:

	Domestic	Outside US	Total
Obstetrics	$ 1,014	$ 232	$ 1,246
Gynecology/Electrosurgery/Urology	2,743	2,815	5,558
Neonatal	1,336	312	1,648
Blood Pressure Monitoring and Accessories*	2,656	1,464	4,120
Total:	$ 7,749	$ 4,823	$ 12,572

Global 9M 2021 revenues (USD) by product category:

	Domestic	Outside US	Total
Obstetrics	$ 2,864	$ 559	$ 3,423
Gynecology/Electrosurgery/Urology	8,229	8,130	16,359
Neonatal	3,813	1,064	4,877
Blood Pressure Monitoring and Accessories*	7,649	3,832	11,481
Total:	$ 22,555	$ 13,585	$ 36,140

*includes molded components sold to OEM customers.

Looking forward, UTMD expects that its 4Q 2021 and year 2022 organic device sales will continue to improve.

Table of Contents

c)Gross Profit

Gross Profit results from subtracting the costs of manufacturing products, including relatively fixed critical mass of overhead expenses associated with quality assurance, engineering and supervision, from revenues. Gross Profit was $1,576 (+24.3%) higher in 3Q 2021 than in 3Q 2020, and $4,522 (+24.7%) higher in 9M 2021 than in 9M 2020. UTMD’s 3Q 2021 Gross Profit Margin (GPM) (Gross Profit/ Sales) improved to 64.2% compared to 62.0% in 3Q 2020, and to 63.1% compared to 60.6% in 9M 2021 compared to 9M 2020. The GPM expansion in both periods allowed a higher increase in Gross Profit than in revenues. In 2020, UTMD did not reduce critical mass manufacturing overhead expenses in proportion to its temporary pandemic decline in sales. As a result, the 2021 GPM has expanded as a result of UTMD not needing to increase manufacturing overhead expenses in proportion to the sales recovery. Looking forward, UTMD management expects new pressure on its GPM as a result of recent increases in raw material and packaging costs in the range of 8%-15%, a more than doubling of freight costs associated with obtaining materials from vendors, a recent 5% cost-of-living adjustment for its direct labor force, and higher sterilization costs, among other cost increases. Management believes, however, that UTMD does retain the ability to adjust prices for its specialty devices to allow it to continue to achieve its minimum GPM target of 60%.

d)Operating Income

Operating Income results from subtracting Operating Expenses from Gross Profit. Operating Expenses, comprised of general and administrative (G&A) expenses, sales and marketing (S&M) expenses and product development (R&D) expenses, were 23.7% of sales in 3Q 2021 compared to 27.8% of sales in 3Q 2020. Operating Expenses were 25.1% of sales in 9M 2021 compared to 29.4% of sales in 9M 2020. The operating expense percentage of sales declined in 3Q 2021 as a result of expenses increasing only 2.3% when sales increased 20.0%, and in 9M 2021 when Operating Expense increased only 2.2% when sales increased 19.8%.

Summary comparison of (USD) consolidated operating expenses:

	3Q 2021	3Q 2020	9M 2021	9M 2020
S&M Expense	$ 324	$ 352	$ 1,071	$ 1,195
R&D Expense	126	125	385	375
G&A Expense	2,524	2,432	7,598	7,285
Total Operating Expenses:	$ 2,974	$ 2,909	$ 9,054	$ 8,855

A weaker USD helped increase consolidated USD sales in 2021, but it also helped increase the USD-denominated operating expenses of UTMD’s foreign subsidiaries by $49 in 3Q 2021 and $221 in 9M 2021. In “constant currency” terms, operating expenses in 3Q and 9M 2021 were almost the same as in the prior year:

	3Q 2021 const FX	3Q 2020	9M 2021 const FX	9M 2020
S&M Expense	$ 321	$ 352	$ 1,049	$ 1,195
R&D Expense	126	125	384	375
G&A Expense	2,478	2,432	7,400	7,285
Total Operating Expenses:	$ 2,925	$ 2,909	$ 8,833	$ 8,855

Table of Contents

The following lower operating expense ratios in 2021 were essentially due to higher sales, rather than the change in actual expenses.

S&M expenses were 2.6% of sales in 3Q 2021 and 3.4% of sales in 3Q 2020. S&M expenses were 3.0% of sales in 9M 2021 compared to 4.0% of sales in 9M 2020. Somewhat lower actual S&M expenses were due primarily to one less sales person in the U.S.

R&D expenses were 1.0% of sales in 3Q 2021 compared to 1.2% of sales in 3Q 2020. R&D expenses in 9M 2021 were 1.1% of sales compared to 1.2% of sales in 9M 2020. R&D expenses varied only by specific project expenses.

Consolidated G&A expenses were 20.1% of sales in 3Q 2021 compared to 23.2% of sales in 3Q 2020. Consolidated G&A expenses were 21.0% of sales in 9M 2021 compared to 24.2% of sales in 9M 2020. G&A expenses included non-cash expense from the amortization of IIA resulting from the March 2011 Femcare Group Ltd (UK) acquisition and the amortization of IIA from the purchase of the CSI exclusive Filshie devices U.S. distribution rights effective in February 2019.

The initial amount of IIA for the 2011 Femcare UK purchase was £23,998. After 10.5 years of amortization, the IIA balance is £7,094. For 3Q 2021 and 3Q 2020, the IIA amortization expenses were £397 and £399 respectively. For 9M 2021 and 9M 2020, the IIA amortization expenses were £1,193 and £1,196 respectively. The USD amortization expense amount in each period, however, varied according to the USD/GBP FX rate which explains the differences in IIA amortization expenses in the table below.

The initial amount of IIA for the 2019 acquisition of 4.75 years’ remaining exclusive U.S. Filshie device distribution rights from CSI was $21,000. The straight-line amortization of this IIA is $1,105/ calendar quarter over the remaining 4.75 years of the prior distribution agreement. After 32 months of amortization, the CSI IIA balance as of September 30, 2021 is $9,211. The CSI IIA amortization expenses were the same in both years’ 3Q and 9M periods.

Because the IIA amortization expenses represent a significant portion of UTMD’s G&A expenses, UTMD provides the following table that separates the IIA amortization expenses from all other G&A expenses:

	3Q 2021	3Q 2020	9M 2021	9M 2020
IIA amortization expense	$ 1,653	$ 1,621	$ 4,969	$ 4,839
All other G&A expense	871	811	2,629	2,445
Total G&A Expenses:	$ 2,524	$ 2,432	$ 7,598	$ 7,284

Percent of Sales:	3Q 2021	3Q 2020	9M 2021	9M 2020
IIA amortization expense	13.1%	15.5%	13.7%	16.0%
All other G&A expense	7.0%	7.7%	7.3%	8.1%
Total G&A Expenses:	20.1%	23.2%	21.0%	24.1%

Eventually, when the two Filshie-related IIA balances are fully amortized, stockholders can look forward to a substantial increase in EBT. The Femcare acquisition IIA amortization expense has 4.5 more years to run at about $547 per quarter using the same USD/GBP FX rate as in 3Q 2021. The CSI IIA amortization expense has 2.1 more years to run at $1,105 per quarter. Stockholders will appreciate that, although cash flow will not be affected, annualized reported EPS will increase $.90 after another 2.1 years, based on current shares outstanding and if current U.S. and Utah income tax rates remain the same. Similarly, after another 4.5 years annualized EPS would be $1.35 higher based on current shares outstanding and a 25% income tax rate in the UK beginning in April 2023.

Other G&A expenses were higher in both periods primarily because UTMD’s CEO took 50% salary in 2020, and 2021 employee profit-sharing bonuses based on the projected 2021 annual EBT have been accrued at a higher rate than in 2020.

In summary, Operating Income in 3Q 2021 was $5,098 (40.6% of sales) compared to $3,588 (34.2% of sales) in 3Q 2020. Operating Income in 9M 2021 was $13,750 (38.0% of sales) compared to $9,428 (31.3% of sales) in 9M 2020. A higher GPM on higher sales in 2021 was leveraged further by lower Operating Expenses as a ratio of sales.

e)Non-operating expense/ Non-operating income

Non-operating expense includes 1) bank fees; 2) losses from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) losses from disposition of assets. Non-operating income includes 1) investment income from cash deposit balances; 2) rent of underutilized property; 3) royalties received from licensing the Company’s technology; 4) gains from dispositions of assets; and 5) gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms.

Table of Contents

UTMD’s net non-operating income in 3Q 2021 was $59 compared to less than $1 in 3Q 2020. Net non-operating income in 9M 2021 was $130 compared to $126 in 9M 2020.

In 3Q 2021 and 3Q 2020, losses from remeasurement of the value of foreign currency bank balances were negligible in both periods. In 9M 2021, UTMD recognized a $13 loss from remeasurement of the value of foreign currency bank balances compared to a $41 gain in 9M 2020. Royalties received were $10 in 3Q 2021 compared to $5 in 3Q 2020, and $10 in 9M 2021 compared to $10 in 9M 2020. Interest earned on cash balances were $6 and $31 in 3Q and 9M 2021 respectively, compared to interest of $2 and $64 in 3Q and 9M 2020 respectively.

f)Income Before Income Taxes (EBT)

EBT results from subtracting net non-operating expense or adding net non-operating income from or to, as applicable, Operating Income. Consolidated 3Q 2021 EBT was $5,157 (41.0% of sales) compared to $3,588 (34.2% of sales) in 3Q 2020. Consolidated 9M 2021 EBT was $13,880 (38.4% of sales) compared to $9,553 (31.7% of sales) in 9M 2020.

The EBT of Utah Medical Products, Inc. in the U.S. was $8,736 in 9M 2021 compared to $6,469 in 9M 2020. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 4,662 in 9M 2021 compared to EUR 2,393 in 9M 2020. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (361) in 9M 2021 compared to GBP (297) in 9M 2020. The EBT of Utah Medical Products Canada, Inc. (dba Femcare Canada) was CAD 450 in 9M 2021 compared to CAD 565 in 9M 2020. The EBT of UTMD’s manufacturing subsidiaries varies as a result of intercompany shipments which are eliminated in the consolidation of results.

EBITDA is a non-US GAAP metric that UTMD management believes is of interest to investors because it provides meaningful supplemental information to both management and investors that represents profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Although the U.S. Securities and Exchange Commission advises that EBITDA is a non-GAAP metric, UTMD’s non-US GAAP EBITDA is the sum of the following elements in the table below, each of which is a US GAAP number:

Component of EBITDA	3Q 2021	3Q 2020	Change	9M 2021	9M 2020	Change
EBT	$ 5,157	$ 3,588	+43.7%	$ 13,880	$ 9,553	+45.3%
Depreciation of fixed assets	157	160		483	495
Amortization of patent expenses	9	12		27	37
Amortization of Femcare IIA	548	517		1,653	1,523
Amortization of CSI distribution agreement IIA	1,105	1,105		3,316	3,316
Stock option compensation expense	41	49		123	121
Remeasured currency (gains) or losses	7	2		13	(41)
Adjusted Consolidated EBITDA:	$ 7,024	$ 5,433	+29.3%	$19,495	$15,004	+29.9%

Management believes that the non-US GAAP EBITDA improvement is more indicative of UTMD’s recovery from the COVID-19 negative impact on UTMD’s 2020 operating results than the change represented by EBT.

g)Net Income

Net Income is EBT minus a provision for income taxes. Net Income in 3Q 2021 was $4,206 (33.5% of sales) compared to $2,933 (28.0% of sales) in 3Q 2020. The average consolidated income tax provision (as a % of EBT) in 3Q 2021 was 18.4% compared to 18.3% in 3Q 2020.

Net Income in 9M 2021 was $10,656 (29.5% of sales) compared to Net Income of $7,386 (24.5% of sales) in 9M 2020. Net Income in 9M 2021 included a 2Q 2021 unfavorable $390 tax provision increase for a future UK income tax increase on non-deductible IIA amortization expense beginning in 2023. Net Income in 9M 2020 included a 2Q 2020 unfavorable $225 tax provision increase for a future UK income tax increase on non-deductible IIA amortization expense over the ensuing six years. The average consolidated income tax provisions (as a % of EBT) in 9M 2021 and 9M 2020 were 23.2% and 22.7%, respectively.

Table of Contents

h)Earnings Per Share (EPS)

EPS are consolidated Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are “in the money,” i.e., have exercise prices below the applicable period’s weighted average market value).

Diluted EPS in 3Q 2021 were $1.150 compared to $.803 in 3Q 2020. Diluted US GAAP EPS in 9M 2021 were $2.915 compared to $2.008 in 9M 2020. According to U.S. GAAP, the UK tax law change in 2Q 2021 which increased UTMD’s deferred tax liability as a result of the UK corporate tax rate increasing to 25% in 2023, and the UK tax law change in 2Q 2020, resulted in income tax provision increases in both the 2Q 2021 and the 2Q 2020 income statements. Without the $390 tax provision adjustment in 2Q 2021, 9M 2021 non-US GAAP EPS were $3.021. Without the $225 tax provision adjustment in 2Q 2020, 9M 2020 non-US GAAP EPS were $2.069.

Diluted shares were 3,657,733 in 3Q 2021 compared to 3,653,500 in 3Q 2020, and 3,656,255 in 9M 2021 compared to 3,678,210 in 9M 2020. The differences in diluted shares resulted from employee option exercises, shares repurchased during 2020, an employee option award in 2020, and the time-weighted calculation of outstanding shares and options “in the money” at an average applicable period stock price. The number of shares added as a dilution factor in 3Q 2021 was 10,933 compared to 11,130 in 3Q 2020. The number of shares added as a dilution factor in 9M 2021 was 10,685 compared to 14,514 in 9M 2020. In March 2020, 26,300 option shares were awarded to 48 employees at an exercise price of $77.05 per share. No options have been awarded in 2021. In March 2020, UTMD repurchased 80,000 of its shares in the open market at $80.32/ share. In September 2020, UTMD repurchased 7,000 of its shares in the open market at $78.67/ share. The total 87,000 shares repurchased in 9M 2020 were at an average price of $80.19/ share. No shares have been repurchased in 2021. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.

Outstanding shares at the end of 3Q 2021 were 3,648,984 compared to 3,643,035 at the end of calendar year 2020. The difference was due to employee option exercises of 5,949 shares during 9M 2021. Outstanding shares were 3,640,371 one year ago at the end of 3Q 2020. The number of shares used for calculating diluted EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. The total number of outstanding unexercised employee and outside director options at September 30, 2021 was 59,869 at an average exercise price of $68.74, including shares awarded but not yet vested. This compares to 71,700 unexercised option shares at the end of 3Q 2020 at an average exercise price of $65.80/ share, including shares awarded but not yet vested.

UTMD distributed $1,039 ($0.285/share) in dividends to stockholders in 3Q 2021 compared to $1,020 ($0.280/ share) distributed in 3Q 2020. Dividends paid to stockholders during 3Q 2021 were 25% of 3Q 2021 Net Income. UTMD paid $3,116 ($0.285/share) in dividends to stockholders in 9M 2021 compared to $3,097 ($0.280/ share) paid in 9M 2020. Dividends paid to stockholders during 9M 2021 were 28% of 9M 2021 Net Income.

i) Return on Stockholder Equity (ROE) and Stock Value

ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated stockholders’ equity for the applicable time period. After payment of cash dividends to stockholders, annualized ROE in 9M 2021 was 10% compared to annualized ROE of 6% in 9M 2020. Before the payment of dividends, annualized ROE in 9M 2021 was 14% compared to 10% in 9M 2020. The higher ROE in 9M 2021 was due to a 7% increase in average accumulated stockholders’ equity together with a 44% decrease in Net Income. Targeting a high ROE of 20% (before dividends) remains a key financial objective for UTMD management.

UTMD’s closing share price at the end of 3Q 2021 was $92.84, up 10% from the $84.30 closing price at the end of 2020. The closing share price at the end of 3Q 2020 was $79.87.

Liquidity and Capital Resources

j)Cash flows

Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $16,217 in 9M 2021 compared to $14,359 in 9M 2020. The $1,857 higher cash provided by operating activities in 9M 2021 was due primarily to differences from $3,271 higher net income offset by greater net $1,269 decreases in working capital from 1) $926 decreased trade accounts receivable and inventories compared to a $1,184 increase in 9M 2020, yielding a $2,110 lower working capital change difference in the two periods, and 2) a $1,053 increase in accounts payable and accrued expenses compared to a $212 increase in 9M 2020, yielding a $841 higher working capital change difference in the two periods.

Table of Contents

Capital expenditures for property and equipment (PP&E) were $299 in 9M 2021 compared to $806 in 9M 2020. The higher capital expenditures in 2020 were due to a new roof on the Midvale facility and investment in new manufacturing capabilities in Ireland. There were no capital expenditures for intangible assets in either 9M 2021 or 9M 2020.

UTMD made cash dividend payments of $3,116 in 9M 2021 compared to $3,097 in 9M 2020. There were no share repurchases in 9M 2021. The Company used $6,976 of its cash to repurchase 87,000 of its own shares in 9M 2020.

In 9M 2021 the Company received $281 and issued 5,949 shares of stock on the exercise of employee and director stock options. Option exercises in 9M 2021 were at an average price of $47.25 per share. In comparison, in 9M 2020, UTMD received $282 and issued 5,614 shares of its stock upon the exercise of employee and director stock options. Option exercises in 9M 2020 were at an average price of $50.15 per share.

Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company may utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD’s existing infrastructure. If there are no better strategic uses for UTMD’s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.

k)Assets and Liabilities

September 30, 2021 total consolidated assets were $119,752, a net increase of $8,007 from December 31, 2020. Primarily as a result of the increase in cash, consolidated current assets increased $13,584. The total asset increase was due to a $12,731 increase in cash plus a $749 increase in net accounts and other receivables, a $77 increase in inventories and a $27 increase in other current assets, offset by decreases of $5,183 in Net Intangible Assets and $394 in net consolidated Property, Plant and Equipment (PP&E). The decreases in Net Intangibles and PP&E were due to a combination of depreciation exceeding new purchases and amortization of Intangibles combined with changes in FX rates for OUS assets.

UTMD’s Ireland subsidiary EUR-denominated assets and liabilities on September 30, 2021 were translated into USD at an FX rate 5.3% lower (weaker EUR relative to the USD) than the FX rate at the end of 2020. UTMD’s UK subsidiary GBP-denominated assets were translated into USD at an FX rate 1.4% lower (weaker GBP) than the FX rate at the end of 2020. UTMD’s Australia subsidiary AUD-denominated assets were translated into USD at an FX rate 6.2% lower (weaker AUD) than the FX rate at the end of 2020. UTMD’s Canada subsidiary CAD-denominated assets were translated into USD at an FX rate 0.6% higher (stronger CAD) than the FX rate at the end of 2020. The net book value of PP&E declined $394 at September 30, 2021 from the end of 2020 due to the period-ending changed FX rates above, $299 in new asset purchases and $483 in depreciation.

Working capital (current assets minus current liabilities) was $70,830 at September 30, 2021 compared to $58,471 at December 31, 2020. The whole source of the working capital increase was from an increase of $12,731 in cash. Consolidated receivables and inventories increased $749 and $77, respectively, but current liabilities also increased $1,225. The current liabilities of accounts payable and accrued liabilities increased $238 and $986 respectively, due to higher sales/production activity and higher accrued income taxes. UTMD management believes that its working capital remains sufficient to meet normal operating needs, new capital expenditures and continued cash dividend payments to stockholders.

September 30, 2021 net intangible assets (goodwill plus other intangible assets less amortization) declined $5,183 from the end of 2020. No new intangible assets were acquired in 9M 2021. At September 30, 2021, net intangible assets including goodwill were 28% of total consolidated assets compared to 34% at year-end 2020, and 36% at September 30, 2020.

The long term deferred tax liability (DTL) balance for Femcare IIA ($9,084 on the date of the acquisition) was $2,196 (£1,630) at September 30, 2021, compared to $2,151 (£1,575) at December 31, 2020, and $2,132 (£1,650) at September 30, 2020. Reduction of the DTL occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare IIA (because the amortization expense is not tax deductible in the UK). The DTL increased $45 at September 30, 2021 from December 31, 2020, despite 9M 2021 amortization expense of $1,654, which reduced the DTL balance by $314 (using UK tax rate = 19%). The difference was due to a UK tax law change enacted in 2Q 2021 which increased the DTL balance by $390 (£283), combined with a change in ending FX rates. The UK increased its corporate income tax rate from 19% to 25% beginning April 1, 2023, which affects non-deductible amortization expense after March 31, 2023. (The $390 increase in deferred UK taxes was booked in the 2Q 2021 tax provision, reducing 9M 2021 net income $390.)

UTMD’s total debt ratio (total liabilities/ total assets) as of September 30, 2021 was 8%, including a remaining $2,047 REPAT tax liability payable over another four years. The total debt ratio as of December 31, 2020, as well as of September 30, 2020, was also 8%.

The $8,007 increase in total liabilities and stockholders’ equity (same as in total assets) was primarily due to a $7,158 September 30, 2021 ending increase in stockholders’ equity compared to December 31, 2020. Stockholders’ equity was increased during 9M 2021 by $10,656 US GAAP Net Profit minus $3,116 in dividends paid to stockholders.

Table of Contents

l)Management's Outlook

As outlined in its December 31, 2020 SEC 10-K report, UTMD’s general plan for 2021 was to

1) exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations;

2) focus on effective direct marketing of the benefits of the Filshie Clip System in the U.S.;

3) introduce additional products helpful to clinicians through internal new product development;

4) continue to achieve excellent overall financial operating performance;

5) utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued; and

6) be vigilant for accretive acquisition opportunities which may be brought about by difficult burdens on small, innovative companies.

The Company has recovered better than expected from the COVID-19 pandemic, exceeding targeted 2019 financial performance prior to the pandemic.

m)Accounting Policy Changes

None

Forward-Looking Information. This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. When used in this document, the words “anticipate,” “believe,” “project,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and, starting in 2017, in Canada denominated in the Canadian Dollar (CAD). The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. The exchange rates were .8638, .8178 and .8529 EUR per USD as of September 30, 2021, December 31, 2020 and September 30, 2020, respectively. Exchange rates were .7425, .7318 and .7741 GBP per USD as of September 30, 2021, December 31, 2020 and September 30, 2020, respectively. Exchange rates were 1.3834, 1.2974 and 1.3964 AUD per USD on September 30, 2021, December 31, 2020, and September 30, 2020, respectively. Exchange rates were 1.2673, 1.2754, and 1.3323 CAD per USD on September 30, 2021, December 31, 2020, and September 30, 2020, respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur, and by optimizing global account structures through liquidity management accounts.

Item 4. Controls and Procedures

The Company’s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of September 30, 2021. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of September 30, 2021, the Company’s disclosure controls and procedures were effective.

There were no changes in the Company’s internal controls over financial reporting that occurred during the nine months ended September 30, 2021, that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company may be a party from time to time in litigation incidental to its business. Presently, there is no litigation the outcome of which is expected to be material to financial results.

Item 1A. Risk Factors

In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in UTMD’s Annual Report on Form 10-K for the year ended December 31, 2020, which could materially affect its business, financial condition or future results. The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

Legislative or executive order healthcare interference in the United States renders the U.S. medical device marketplace unpredictable. A fully government-run healthcare system would likely eliminate healthcare consumer choice as well as commercial incentives for innovation. Restrictions on “nonessential” medical procedures during a pandemic reduce the demand for certain of UTMD’s medical devices.

Increasing regulatory burdens, including premarketing approval delays, may result in significant loss of revenue, unpredictable costs and loss of management focus on developing and marketing products that improve the quality of healthcare:

Thousands of small focused medical device manufacturers including UTMD that do not have the overhead structure that the few large medical device companies can afford are increasingly burdened with bureaucratic and underqualified regulator demands that are not reasonably related to assuring the safety or effectiveness of the devices that they provide. Premarketing submission administrative burdens, and substantial “user fees” or notified body review fees, represent a significant non-clinical and/or non-scientific barrier to new product introduction, resulting in lack of investment or delays to revenues from new or improved devices. The risks associated with such circumstances relate not only to substantial out-of-pocket costs, including potential litigation in millions of dollars, but also loss of business and a diversion of attention of key employees for an extended period of time from managing their normal responsibilities, particularly in new product development and routine quality assurance activities.

Group Purchasing Organizations (GPOs) add non-productive costs, weaken the Company’s marketing and sales efforts and cause lower revenues by restricting access:

GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD’s, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Otherwise, their business model based on “kickbacks” would be a violation of law. Despite rhetoric otherwise, these bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily driven by collection of administrative fees.

The Company’s business strategy may not be successful in the future:

As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable and overly cumbersome regulatory environment, the Company’s views of the future and product/ market strategy may not yield financial results consistent with the past.

As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage:

An aging population is placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD’s clinical advantages much more difficult.

Table of Contents

A product liability lawsuit could result in significant legal expenses and a large award against the Company:

UTMD’s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. In any lawsuit where an individual plaintiff suffered permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists.

The Company’s reliance on third party distributors in some markets may result in less predictable revenues:

UTMD’s distributors have varying expertise in marketing and selling specialty medical devices. They also sell other devices that may result in less focus on the Company’s products. In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, a distributor of UTMD’s products may eventually become a competitor with a cheaper but lower quality version of UTMD’s devices.

The loss of one or more key employees could negatively affect UTMD performance:

In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. The Company’s benefits programs are key to recruiting and retaining talented employees. An increase in UTMD’s employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.

Fluctuations in foreign currencies relative to the USD can result in significant differences in period-to-period financial results:

Since a significant portion of UTMD’s sales are invoiced in foreign currencies and consolidated financial results are reported in USD terms, a stronger USD can have negative revenue effects. Conversely, a weaker USD would increase foreign subsidiary operating costs in USD terms. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. For the portion invoiced in a foreign currency, not only USD-denominated sales are reduced, but also gross profits may be reduced because finished distributed devices and/or U.S. made raw materials and components are likely being purchased in fixed USD.

Trade restrictions and /or tariffs resulting from changing government trade policies have the potential to disrupt UTMD’s supply chain.

The corona virus pandemic could potentially disrupt UTMD’s supply chain or interfere with normal business operations due to the loss of employee availability.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

UTMD did not purchase any of its own securities during 9M 2021. During 9M 2020 UTMD purchased 87,000 of its shares in the open market for $6,976 including commissions and fees.

Item 6. Exhibits

Exhibit #	Title of Document

31.1	Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1	Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101	The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders’ Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UTAH MEDICAL PRODUCTS, INC.

REGISTRANT

Date: 11/12/21 By: /s/ Kevin L. Cornwell

Kevin L. Cornwell

CEO

Date: 11/12/21 By: /s/ Brian L. Koopman

Brian L. Koopman

Principal Financial Officer

EX-31.1 2 utmd_ex31z1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CEO

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin L. Cornwell, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2021

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

EX-31.2 3 utmd_ex31z2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brian L. Koopman, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2021

/s/ Brian L. Koopman

Brian L. Koopman

Principal Financial Officer

EX-32.1 4 utmd_ex32z1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

November 12, 2021

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 utmd_ex32z2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Brian L. Koopman

Brian L. Koopman

Principal Financial Officer

November 12, 2021

EX-101.CAL 6 utmd-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 utmd-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 utmd-20210930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Obstetrics Represents the Obstetrics, during the indicated time period. Basis of Presentation Total stockholders' equity Total stockholders' equity Accounts payable Total current assets Total current assets Entity Address, Postal Zip Code Entity Address, Address Line One Stock-Based Compensation Amortization CASH FLOWS FROM OPERATING ACTIVITIES: Accumulated other comprehensive income (loss) Other intangible assets Local Phone Number Entity Small Business Entity Filer Category Standard and Extended Product Warranty Accrual Earnings Per Share Net increase in cash and cash equivalents Net increase in cash and cash equivalents Accounts receivable and other receivables Accounts receivable and other receivables Depreciation Additional Paid-in Capital Stockholders' equity: Entity File Number Well-known Seasoned Issuer Distribution Rights Acquisition Represents the Distribution Rights Acquisition, during the indicated time period. Revenue Recognition (Gain) loss on disposal of assets (Gain) loss on disposal of assets Provision for (recovery of) losses on accounts receivable Common stock received and retired upon exercise of stock options, shares Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period. Comprehensive Income Statement Foreign currency translation adjustment Foreign currency translation net of taxes of $0 in all periods Total liabilities and stockholders' equity Total liabilities and stockholders' equity Retained earnings ASSETS Document Fiscal Period Focus Title of 12(b) Security Entity Incorporation, State or Country Code Gynecology/Electrosurgery/Urology Represents the Gynecology/Electrosurgery/Urology, during the indicated time period. Warranty Reserve Changes in operating assets and liabilities: Adjustments to reconcile net income to net cash provided by operating activities: Common stock purchased and retired, shares Equity Balance, shares Equity Balance, shares Equity Balance, shares Equity Balance, value Equity Balance, value Equity Balance, value Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2021, 3,649 shares and December 31, 2020, 3,643 shares Inventories Total Entity Current Reporting Status Blood Pressure Monitoring and Accessories Represents the Blood Pressure Monitoring and Accessories, during the indicated time period. Statement [Line Items] Other comprehensive income (loss): Earnings per share, diluted Earnings per common share (diluted) Accrued expenses Cash & investments Cash at beginning of period Cash at end of period Entity Address, City or Town Amendment Description Entity Shell Company Trading Symbol DomesticUsMember Represents the DomesticUsMember, during the indicated time period. Net cash used in investing activities Net cash used in investing activities Property and equipment Property and equipment Total adjustments Total adjustments Accounts payable {1} Accounts payable Tax benefit attributable to exercise of stock options Common stock purchased and retired Diluted shares Shares outstanding - diluted Net income Net income Income before provision for income taxes Income before provision for income taxes Common Stock, Shares, Outstanding Total liabilities Total liabilities Deferred income taxes Accounts & other receivables, net Ex Transition Period Finished goods Tables/Schedules Deferred income taxes {1} Deferred income taxes Other income Gross profit Gross profit Current Fiscal Year End Date CASH FLOWS FROM FINANCING ACTIVITIES: Inventories {1} Inventories Selling, general and administrative Entity Common Stock, Shares Outstanding Dilutive effect of stock options Finite-lived Intangible Assets Acquired Subsequent Events Effect of exchange rate changes on cash Accrued expenses {1} Accrued expenses Amortization of Right of Use Assets Operating Lease, Right of Use Asset Amortization. Common stock dividends Common stock dividends Equity Component Retained Earnings Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Earnings per share, basic Earnings per common share (basic) Total operating expenses Total operating expenses Amendment Flag Entity Address, State or Province Document Transition Report Document Period End Date CooperSurgical Inc Represents the CooperSurgical Inc, during the indicated time period. Distribution Rights Acquisition [Axis] Represents the description of Distribution Rights Acquisition, during the indicated time period. Product and Service [Axis] Geographical [Axis] Common stock purchased and retired {1} Common stock purchased and retired Stock-based compensation expense Equity Components [Axis] Current liabilities: Details Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period. Neonatal Represents the Neonatal, during the indicated time period. Raw materials Net cash provided by operating activities Net cash provided by operating activities Common stock issued upon exercise of employee stock options Operating lease liability LIABILITIES AND STOCKHOLDERS' EQUITY Current assets: City Area Code Entity Emerging Growth Company Entity Tax Identification Number OutsideUsMember Represents the OutsideUsMember, during the indicated time period. Schedule of Inventory, Current Cash paid during the period for interest Net cash used in financing activities Net cash used in financing activities CASH FLOWS FROM INVESTING ACTIVITIES: Prepaid expenses and other current assets Prepaid expenses and other current assets Additional paid-in capital Deferred tax liability - Femcare IIA Other intangible assets, net Other intangible assets, net Operating lease - right-of-use assets, net Public Float Document Type Allocated Share-based Compensation Expense New Accounting Pronouncements and Changes in Accounting Principles Payment of dividends Payment of dividends Proceeds from issuance of common stock - options Operating income Operating income Sales, net Other intangible assets - accumulated amortization Other intangible assets - accumulated amortization Document Quarterly Report Entity Central Index Key Geographical Schedule Of Revenues By Product Category Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period. Common stock received and retired upon exercise of stock options Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period. Common Stock Weighted average shares, basic Shares outstanding - basic Provision for income taxes Research & development Cost of goods sold Common Stock, Par or Stated Value Per Share Other long term liabilities Total current liabilities Total current liabilities Total assets Total assets Property and equipment, net Product and Service Work-in-process Inventories {2} Inventories Cash paid during the period for income taxes Operating expense Common Stock, Shares Authorized Goodwill Document Fiscal Year Focus Entity Interactive Data Current Schedule of Earnings Per Share, Basic and Diluted New Accounting Pronouncements, Policy Policies CSI Distribution Agreement Purchase Disclosure Notes Stock option compensation expense Common stock issued upon exercise of employee stock options, shares Total comprehensive income Total comprehensive income Common Stock, Shares, Issued Other current assets Security Exchange Name Voluntary filer Entity Registrant Name EX-101.PRE 9 utmd-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 utmd-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Warranty Reserve link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Revenue Recognition link:presentationLink link:definitionLink link:calculationLink 000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Warranty Reserve (Details) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink XML 11 utmd-20210930_htm.xml IDEA: XBRL DOCUMENT 0000706698 2021-01-01 2021-09-30 0000706698 2021-09-30 0000706698 2020-06-30 0000706698 2021-11-11 0000706698 2020-12-31 0000706698 2021-07-01 2021-09-30 0000706698 2020-07-01 2020-09-30 0000706698 2020-01-01 2020-09-30 0000706698 2019-12-31 0000706698 2020-09-30 0000706698 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000706698 us-gaap:ComprehensiveIncomeMember 2021-01-01 2021-09-30 0000706698 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000706698 2021-06-30 0000706698 us-gaap:CommonStockMember 2021-06-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000706698 us-gaap:ComprehensiveIncomeMember 2021-06-30 0000706698 us-gaap:RetainedEarningsMember 2021-06-30 0000706698 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000706698 us-gaap:ComprehensiveIncomeMember 2021-07-01 2021-09-30 0000706698 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000706698 us-gaap:CommonStockMember 2021-09-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000706698 us-gaap:ComprehensiveIncomeMember 2021-09-30 0000706698 us-gaap:RetainedEarningsMember 2021-09-30 0000706698 us-gaap:CommonStockMember 2020-12-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000706698 us-gaap:ComprehensiveIncomeMember 2020-12-31 0000706698 us-gaap:RetainedEarningsMember 2020-12-31 0000706698 us-gaap:CommonStockMember 2020-06-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000706698 us-gaap:ComprehensiveIncomeMember 2020-06-30 0000706698 us-gaap:RetainedEarningsMember 2020-06-30 0000706698 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000706698 us-gaap:ComprehensiveIncomeMember 2020-07-01 2020-09-30 0000706698 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000706698 us-gaap:CommonStockMember 2020-09-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000706698 us-gaap:ComprehensiveIncomeMember 2020-09-30 0000706698 us-gaap:RetainedEarningsMember 2020-09-30 0000706698 us-gaap:CommonStockMember 2019-12-31 0000706698 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000706698 us-gaap:ComprehensiveIncomeMember 2019-12-31 0000706698 us-gaap:RetainedEarningsMember 2019-12-31 0000706698 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000706698 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000706698 us-gaap:ComprehensiveIncomeMember 2020-01-01 2020-09-30 0000706698 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000706698 fil:DomesticUsMember 2021-01-01 2021-09-30 0000706698 fil:OutsideUsMember 2021-01-01 2021-09-30 0000706698 fil:ObstetricsMember 2021-01-01 2021-09-30 0000706698 fil:ObstetricsMember fil:DomesticUsMember 2021-07-01 2021-09-30 0000706698 fil:ObstetricsMember fil:OutsideUsMember 2021-07-01 2021-09-30 0000706698 fil:ObstetricsMember 2021-07-01 2021-09-30 0000706698 fil:GynecologyElectrosurgeryUrologyMember 2021-01-01 2021-09-30 0000706698 fil:GynecologyElectrosurgeryUrologyMember fil:DomesticUsMember 2021-07-01 2021-09-30 0000706698 fil:GynecologyElectrosurgeryUrologyMember fil:OutsideUsMember 2021-07-01 2021-09-30 0000706698 fil:GynecologyElectrosurgeryUrologyMember 2021-07-01 2021-09-30 0000706698 fil:NeonatalMember 2021-01-01 2021-09-30 0000706698 fil:NeonatalMember fil:DomesticUsMember 2021-07-01 2021-09-30 0000706698 fil:NeonatalMember fil:OutsideUsMember 2021-07-01 2021-09-30 0000706698 fil:NeonatalMember 2021-07-01 2021-09-30 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember 2021-01-01 2021-09-30 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember fil:DomesticUsMember 2021-07-01 2021-09-30 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember fil:OutsideUsMember 2021-07-01 2021-09-30 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember 2021-07-01 2021-09-30 0000706698 fil:DomesticUsMember 2021-07-01 2021-09-30 0000706698 fil:OutsideUsMember 2021-07-01 2021-09-30 0000706698 fil:ObstetricsMember fil:DomesticUsMember 2021-01-01 2021-09-30 0000706698 fil:ObstetricsMember fil:OutsideUsMember 2021-01-01 2021-09-30 0000706698 fil:GynecologyElectrosurgeryUrologyMember fil:DomesticUsMember 2021-01-01 2021-09-30 0000706698 fil:GynecologyElectrosurgeryUrologyMember fil:OutsideUsMember 2021-01-01 2021-09-30 0000706698 fil:NeonatalMember fil:DomesticUsMember 2021-01-01 2021-09-30 0000706698 fil:NeonatalMember fil:OutsideUsMember 2021-01-01 2021-09-30 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember fil:DomesticUsMember 2021-01-01 2021-09-30 0000706698 fil:BloodPressureMonitoringAndAccessoriesMember fil:OutsideUsMember 2021-01-01 2021-09-30 0000706698 fil:CoopersurgicalIncMember 2019-01-01 2019-03-31 0000706698 fil:CoopersurgicalIncMember 2021-09-30 2021-09-30 pure iso4217:USD shares iso4217:USD shares 0000706698 --12-31 Yes false 2021 Q3 10-Q true 2021-09-30 false 001-12575 UTAH MEDICAL PRODUCTS INC UT 87-0342734 7043 South 300 West Midvale UT 84047 801 566-1200 Common stock, $0.01 par value UTMD NASDAQ Yes Non-accelerated Filer true false false 3650929

64321000

51590000

4853000

4104000

6299000

6222000

373000

346000

75846000

62262000

10547000

10949000

384000

377000

14064000

14164000

55701000

56159000

36790000

32166000

18911000

23993000

119752000

111745000

1026000

788000

3989000

3003000

5015000

3791000

1810000

2151000

2196000

1995000

343000

335000

408000

651000

9772000

8923000

0.01

50000000

3649000

3643000

36000

-9068000

-8281000

520000

115000

118492000

110952000

109980000

102822000

119752000

111745000

12572000

10479000

36140000

30168000

4499000

3982000

13336000

11885000

8073000

6497000

22804000

18283000

2848000

2785000

8669000

8480000

127000

125000

385000

375000

2975000

2910000

9054000

8855000

5098000

3587000

13750000

9428000

59000

1000

130000

125000

5157000

3588000

13880000

9553000

951000

655000

3224000

2167000

4206000

2933000

10656000

7386000

1.15

0.81

2.92

2.02

1.15

0.80

2.91

2.01

3647000

3642000

3645000

3664000

3658000

3653000

3656000

3678000

-782000

1511000

-787000

-416000

3424000

4444000

9869000

6970000

10656000

7386000

483000

495000

4996000

4875000

20000

-4000

32000 29000

-1000

-160000

-20000

123000

121000

11000

7000

802000

-442000

161000

-757000

35000

-58000

242000

-439000

811000

651000

5560000

6973000

16216000

14359000

299000

806000

-299000

-806000

281000

282000

6977000

3116000

3097000

-2835000

-9792000

-351000

-254000

12731000

3507000

51590000

42787000

64321000

46294000

3094000

2153000

3646000

36000

289000

-8286000

115326000

107365000

3000

189000

41000

-782000

1040000

4206000

3649000

36000

520000

-9068000

118492000

109980000

3643000

36000

115000

-8281000

110951000

102822000

6000

281000

123000

-787000

3116000

10656000

3649000

36000

520000

-9068000

118492000

109980000

3643000

36000

80000

-11710000

106881000

95288000

4000

202000

49000

-7000

-332000

-219000

-551000

1511000

1018000

2933000

3640000

36000

-10199000

108578000

98415000

3722000

37000

18000

-9783000

110820000

101092000

6000

282000

121000

-87000

-1000

-421000

-6555000

-6976000

-416000

3074000

7386000

3640000

36000

-10199000

108578000

98415000

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2020. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards. The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

(3) Inventories at September 30, 2021, and December 31, 2020, consisted of the following: <table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:411.4pt" valign="top"/><td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> September 30, 2021 </td><td style="width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">December 31, 2020 </td></tr> <tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top">Finished goods </td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">$ </td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">1,436 </td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">$ </td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">1,363 </td></tr> <tr><td style="width:411.4pt;padding-right:5.75pt" valign="top">Work-in-process </td><td style="width:31.4pt;padding-right:5.75pt" valign="top"> </td><td style="width:308.6pt;padding-right:5.75pt" valign="top">1,459 </td><td style="width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="width:31.45pt;padding-right:5.75pt" valign="top"> </td><td style="width:288.6pt;padding-right:5.75pt" valign="top">1,375 </td></tr> <tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top">Raw materials </td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">3,404 </td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">3,484 </td></tr> <tr><td style="width:411.4pt;padding-right:5.75pt" valign="top">Total </td><td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">$ </td><td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">6,299 </td><td style="width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">$ </td><td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">6,222 </td></tr> </table>

<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:411.4pt" valign="top"/><td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> September 30, 2021 </td><td style="width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">December 31, 2020 </td></tr> <tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top">Finished goods </td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">$ </td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">1,436 </td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">$ </td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">1,363 </td></tr> <tr><td style="width:411.4pt;padding-right:5.75pt" valign="top">Work-in-process </td><td style="width:31.4pt;padding-right:5.75pt" valign="top"> </td><td style="width:308.6pt;padding-right:5.75pt" valign="top">1,459 </td><td style="width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="width:31.45pt;padding-right:5.75pt" valign="top"> </td><td style="width:288.6pt;padding-right:5.75pt" valign="top">1,375 </td></tr> <tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top">Raw materials </td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">3,404 </td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">3,484 </td></tr> <tr><td style="width:411.4pt;padding-right:5.75pt" valign="top">Total </td><td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">$ </td><td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">6,299 </td><td style="width:24.3pt;padding-right:5.75pt" valign="top"> </td><td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">$ </td><td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">6,222 </td></tr> </table>

1436000

1363000

1459000

1375000

3404000

3484000

6299000

6222000

(4) Stock-Based Compensation. At September 30, 2021, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended September 30, 2021, and 2020, the Company recognized $41 and $49, respectively, in stock based compensation cost. In the nine months ended September 30, 2021, and 2020, the Company recognized $123 and $121, respectively, in stock based compensation cost.

41000

49000

123000

121000

(5) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.” UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2020, or September 30, 2021.

(6) Global 3Q 2021 revenues (USD) by product category: <table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Domestic </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Outside US </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Total </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Obstetrics </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">1,014 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">232 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,246 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Gynecology/Electrosurgery/Urology </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">2,743 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">2,815 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">5,558 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Neonatal </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,336 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">312 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,648 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Blood Pressure Monitoring and Accessories </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">2,656 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">1,464 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">4,120 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Total </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">7,749 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">4,823 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">12,572 </td></tr> </table> Global 9M 2021 revenues (USD) by product category: <table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Domestic </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Outside US </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Total </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Obstetrics </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">2,864 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">559 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">3,423 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Gynecology/Electrosurgery/Urology </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">8,229 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">8,130 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">16,359 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Neonatal </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">3,813 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,064 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">4,877 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Blood Pressure Monitoring and Accessories </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">7,649 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">3,832 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">11,481 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Total </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">22,555 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">13,585 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">36,140 </td></tr> </table>

<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Domestic </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Outside US </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Total </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Obstetrics </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">1,014 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">232 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,246 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Gynecology/Electrosurgery/Urology </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">2,743 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">2,815 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">5,558 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Neonatal </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,336 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">312 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,648 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Blood Pressure Monitoring and Accessories </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">2,656 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">1,464 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">4,120 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Total </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">7,749 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">4,823 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">12,572 </td></tr> </table> Global 9M 2021 revenues (USD) by product category: <table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Domestic </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Outside US </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">Total </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Obstetrics </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">2,864 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">559 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">3,423 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Gynecology/Electrosurgery/Urology </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">8,229 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">8,130 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt" valign="top">16,359 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Neonatal </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">3,813 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">1,064 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top">4,877 </td></tr> <tr><td style="width:180pt;padding-right:5.75pt" valign="top">Blood Pressure Monitoring and Accessories </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">7,649 </td><td style="width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">3,832 </td><td style="width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="width:8.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top">11,481 </td></tr> <tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top">Total </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">22,555 </td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">13,585 </td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top">$ </td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top">36,140 </td></tr> </table>

1014000

232000

1246000

2743000

2815000

5558000

1336000

312000

1648000

2656000

1464000

4120000

7749000

4823000

12572000

2864000

559000

3423000

8229000

8130000

16359000

3813000

1064000

4877000

7649000

3832000

11481000

22555000

13585000

36140000

(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over a remaining 2.08 year life as of September 30, 2021 of the prior CSI distribution agreement with Femcare.

21000000

2.08

(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3rd quarter 2021. The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: <table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">(in thousands) </td><td colspan="3" style="width:336.95pt;padding-right:5.75pt" valign="top">Three months ended </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td colspan="3" style="width:391.35pt;padding-right:5.75pt" valign="top">Nine months ended </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top"> </td><td colspan="3" style="width:336.95pt;padding-right:5.75pt" valign="top">September 30, </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td colspan="3" style="width:391.35pt;padding-right:5.75pt" valign="top">September 30, </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top"/><td style="width:136.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2021 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2020 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2021 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2020 </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Numerator </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td></tr> <tr style="height:11.2pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Net income </td><td style="width:136.65pt;padding-right:5.75pt" valign="middle">4,206 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt" valign="middle">2,933 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt" valign="middle">10,656 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt" valign="middle">7,386 </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:12pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Denominator </td><td style="width:136.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt" valign="top"> </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Weighted average shares, basic </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt" valign="middle">3,647 </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt" valign="middle">3,642 </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle">3,645 </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt" valign="middle">3,664 </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Dilutive effect of stock options </td><td style="width:136.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">11 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">11 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">11 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">14 </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Diluted shares </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,658 </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,653 </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,656 </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,678 </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top"> </td><td style="width:136.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Earnings per share, basic </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt" valign="middle">1.15 </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt" valign="middle">0.81 </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle">2.92 </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt" valign="middle">2.02 </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Earnings per share, diluted </td><td style="width:136.65pt;padding-right:5.75pt" valign="middle">1.15 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt" valign="middle">0.80 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt" valign="middle">2.91 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt" valign="middle">2.01 </td></tr> </table>

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: <table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">(in thousands) </td><td colspan="3" style="width:336.95pt;padding-right:5.75pt" valign="top">Three months ended </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td colspan="3" style="width:391.35pt;padding-right:5.75pt" valign="top">Nine months ended </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top"> </td><td colspan="3" style="width:336.95pt;padding-right:5.75pt" valign="top">September 30, </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td colspan="3" style="width:391.35pt;padding-right:5.75pt" valign="top">September 30, </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top"/><td style="width:136.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2021 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2020 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2021 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">2020 </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Numerator </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"> </td></tr> <tr style="height:11.2pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Net income </td><td style="width:136.65pt;padding-right:5.75pt" valign="middle">4,206 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt" valign="middle">2,933 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt" valign="middle">10,656 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt" valign="middle">7,386 </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:12pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Denominator </td><td style="width:136.65pt;padding-right:5.75pt" valign="top"> </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt" valign="top"> </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt" valign="top"> </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Weighted average shares, basic </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt" valign="middle">3,647 </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt" valign="middle">3,642 </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle">3,645 </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt" valign="middle">3,664 </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Dilutive effect of stock options </td><td style="width:136.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">11 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">11 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">11 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle">14 </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Diluted shares </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,658 </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,653 </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,656 </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">3,678 </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top"> </td><td style="width:136.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"> </td></tr> <tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:321.4pt;padding-right:5.75pt" valign="top">Earnings per share, basic </td><td style="background-color:#CCEEFF;width:136.65pt;padding-right:5.75pt" valign="middle">1.15 </td><td style="background-color:#CCEEFF;width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:161.15pt;padding-right:5.75pt" valign="middle">0.81 </td><td style="background-color:#CCEEFF;width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:184.2pt;padding-right:5.75pt" valign="middle">2.92 </td><td style="background-color:#CCEEFF;width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt" valign="middle">2.02 </td></tr> <tr style="height:12.5pt"><td style="width:321.4pt;padding-right:5.75pt" valign="top">Earnings per share, diluted </td><td style="width:136.65pt;padding-right:5.75pt" valign="middle">1.15 </td><td style="width:39.15pt;padding-right:5.75pt" valign="top"> </td><td style="width:161.15pt;padding-right:5.75pt" valign="middle">0.80 </td><td style="width:46.05pt;padding-right:5.75pt" valign="top"> </td><td style="width:184.2pt;padding-right:5.75pt" valign="middle">2.91 </td><td style="width:34.5pt;padding-right:5.75pt" valign="top"> </td><td style="width:172.65pt;padding-right:5.75pt" valign="middle">2.01 </td></tr> </table>

4206000

2933000

10656000

7386000

3647000

3642000

3645000

3664000

11000

14000

3658000

3653000

3656000

3678000

1.15

0.81

2.92

2.02

1.15

0.80

2.91

2.01

(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Nov. 11, 2021
Details
Entity Registrant Name	UTAH MEDICAL PRODUCTS INC
Entity Central Index Key	0000706698
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Current Fiscal Year End Date	--12-31
Trading Symbol	UTMD
Entity Tax Identification Number	87-0342734
Entity Common Stock, Shares Outstanding		3,650,929
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-12575
Entity Incorporation, State or Country Code	UT
Entity Address, Address Line One	7043 South 300 West
Entity Address, City or Town	Midvale
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84047
City Area Code	801
Local Phone Number	566-1200
Title of 12(b) Security	Common stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3

XML 13 R2.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash & investments	$ 64,321	$ 51,590
Accounts & other receivables, net	4,853	4,104
Inventories	6,299	6,222
Other current assets	373	346
Total current assets	75,846	62,262
Property and equipment, net	10,547	10,949
Operating lease - right-of-use assets, net	384	377
Goodwill	14,064	14,164
Other intangible assets	55,701	56,159
Other intangible assets - accumulated amortization	(36,790)	(32,166)
Other intangible assets, net	18,911	23,993
Total assets	119,752	111,745
Current liabilities:
Accounts payable	1,026	788
Accrued expenses	3,989	3,003
Total current liabilities	5,015	3,791
Deferred tax liability - Femcare IIA	1,810	2,151
Other long term liabilities	2,196	1,995
Operating lease liability	343	335
Deferred income taxes	408	651
Total liabilities	9,772	8,923
Stockholders' equity:
Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2021, 3,649 shares and December 31, 2020, 3,643 shares	36	36
Accumulated other comprehensive income (loss)	(9,068)	(8,281)
Additional paid-in capital	520	115
Retained earnings	118,492	110,952
Total stockholders' equity	109,980	102,822
Total liabilities and stockholders' equity	$ 119,752	$ 111,745

XML 14 R3.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares shares in Thousands	Sep. 30, 2021	Dec. 31, 2020
Details
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	50,000	50,000
Common Stock, Shares, Issued	3,649	3,643
Common Stock, Shares, Outstanding	3,649	3,643

XML 15 R4.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Details
Sales, net	$ 12,572	$ 10,479	$ 36,140	$ 30,168
Cost of goods sold	4,499	3,982	13,336	11,885
Gross profit	8,073	6,497	22,804	18,283
Operating expense
Selling, general and administrative	2,848	2,785	8,669	8,480
Research & development	127	125	385	375
Total operating expenses	2,975	2,910	9,054	8,855
Operating income	5,098	3,587	13,750	9,428
Other income	59	1	130	125
Income before provision for income taxes	5,157	3,588	13,880	9,553
Provision for income taxes	951	655	3,224	2,167
Net income	$ 4,206	$ 2,933	$ 10,656	$ 7,386
Earnings per common share (basic)	$ 1.15	$ 0.81	$ 2.92	$ 2.02
Earnings per common share (diluted)	$ 1.15	$ 0.80	$ 2.91	$ 2.01
Shares outstanding - basic	3,647	3,642	3,645	3,664
Shares outstanding - diluted	3,658	3,653	3,656	3,678
Other comprehensive income (loss):
Foreign currency translation net of taxes of $0 in all periods	$ (782)	$ 1,511	$ (787)	$ (416)
Total comprehensive income	$ 3,424	$ 4,444	$ 9,869	$ 6,970

XML 16 R5.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Details
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	$ 0	$ 0	$ 0	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Comprehensive Income	Retained Earnings	Total
Equity Balance, value at Dec. 31, 2019	$ 37	$ 18	$ (9,783)	$ 110,820	$ 101,092
Equity Balance, shares at Dec. 31, 2019	3,722
Common stock issued upon exercise of employee stock options	$ 0	282	0	0	282
Common stock issued upon exercise of employee stock options, shares	6
Stock option compensation expense	$ 0	121	0	0	121
Common stock purchased and retired	$ (1)	(421)	0	(6,555)	(6,976)
Common stock purchased and retired, shares	(87)
Foreign currency translation adjustment	$ 0	0	(416)	0	(416)
Common stock dividends	0	0	0	(3,074)	(3,074)
Net income	0	0	0	7,386	7,386
Equity Balance, value at Sep. 30, 2020	$ 36	0	(10,199)	108,578	98,415
Equity Balance, shares at Sep. 30, 2020	3,640
Equity Balance, value at Jun. 30, 2020	$ 36	80	(11,710)	106,881	95,288
Equity Balance, shares at Jun. 30, 2020	3,643
Common stock issued upon exercise of employee stock options	$ 0	202	0	0	202
Common stock issued upon exercise of employee stock options, shares	4
Stock option compensation expense	$ 0	49	0	0	49
Common stock purchased and retired	$ 0	(332)	0	(219)	(551)
Common stock purchased and retired, shares	(7)
Foreign currency translation adjustment	$ 0	0	1,511	0	1,511
Common stock dividends	0	0	0	(1,018)	(1,018)
Net income	0	0	0	2,933	2,933
Equity Balance, value at Sep. 30, 2020	$ 36	0	(10,199)	108,578	98,415
Equity Balance, shares at Sep. 30, 2020	3,640
Equity Balance, value at Dec. 31, 2020	$ 36	115	(8,281)	110,951	102,822
Equity Balance, shares at Dec. 31, 2020	3,643
Common stock issued upon exercise of employee stock options	$ 0	281	0	0	281
Common stock issued upon exercise of employee stock options, shares	6
Stock option compensation expense	$ 0	123	0	0	123
Foreign currency translation adjustment	0	0	(787)	0	(787)
Common stock dividends	0	0	0	(3,116)	(3,116)
Net income	0	0	0	10,656	10,656
Equity Balance, value at Sep. 30, 2021	$ 36	520	(9,068)	118,492	109,980
Equity Balance, shares at Sep. 30, 2021	3,649
Equity Balance, value at Jun. 30, 2021	$ 36	289	(8,286)	115,326	107,365
Equity Balance, shares at Jun. 30, 2021	3,646
Common stock issued upon exercise of employee stock options	$ 0	189	0	0	189
Common stock issued upon exercise of employee stock options, shares	3
Stock option compensation expense	$ 0	41	0	0	41
Foreign currency translation adjustment	0	0	(782)	0	(782)
Common stock dividends	0	0	0	(1,040)	(1,040)
Net income	0	0	0	4,206	4,206
Equity Balance, value at Sep. 30, 2021	$ 36	$ 520	$ (9,068)	$ 118,492	$ 109,980
Equity Balance, shares at Sep. 30, 2021	3,649

XML 18 R7.htm IDEA: XBRL DOCUMENT

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 10,656	$ 7,386
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	483	495
Amortization	4,996	4,875
Provision for (recovery of) losses on accounts receivable	20	(4)
Amortization of Right of Use Assets	32	29
(Gain) loss on disposal of assets	0	1
Deferred income taxes	(160)	(20)
Stock-based compensation expense	123	121
Tax benefit attributable to exercise of stock options	11	7
Changes in operating assets and liabilities:
Accounts receivable and other receivables	(802)	442
Inventories	(161)	757
Prepaid expenses and other current assets	(35)	58
Accounts payable	242	(439)
Accrued expenses	811	651
Total adjustments	5,560	6,973
Net cash provided by operating activities	16,216	14,359
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment	(299)	(806)
Net cash used in investing activities	(299)	(806)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	281	282
Common stock purchased and retired	0	(6,977)
Payment of dividends	(3,116)	(3,097)
Net cash used in financing activities	(2,835)	(9,792)
Effect of exchange rate changes on cash	(351)	(254)
Net increase in cash and cash equivalents	12,731	3,507
Cash at beginning of period	51,590	42,787
Cash at end of period	64,321	46,294
Cash paid during the period for income taxes	3,094	2,153
Cash paid during the period for interest	$ 0	$ 0

XML 19 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2021
Notes
Basis of Presentation	(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2020. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

XML 20 R9.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements and Changes in Accounting Principles

9 Months Ended

Sep. 30, 2021

Notes

New Accounting Pronouncements and Changes in Accounting Principles

(2) Recent Accounting Standards.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2021

Notes

Inventories

(3) Inventories at September 30, 2021, and December 31, 2020, consisted of the following:

		September 30, 2021		December 31, 2020
Finished goods	$	1,436	$	1,363
Work-in-process		1,459		1,375
Raw materials		3,404		3,484
Total	$	6,299	$	6,222

XML 22 R11.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2021
Notes
Stock-Based Compensation	(4) Stock-Based Compensation. At September 30, 2021, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended September 30, 2021, and 2020, the Company recognized $41 and $49, respectively, in stock based compensation cost. In the nine months ended September 30, 2021, and 2020, the Company recognized $123 and $121, respectively, in stock based compensation cost.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Warranty Reserve

9 Months Ended

Sep. 30, 2021

Notes

Warranty Reserve

XML 24 R13.htm IDEA: XBRL DOCUMENT

Revenue Recognition

9 Months Ended

Sep. 30, 2021

Notes

Revenue Recognition

(6) Global 3Q 2021 revenues (USD) by product category:

		Domestic		Outside US		Total
Obstetrics	$	1,014	$	232	$	1,246
Gynecology/Electrosurgery/Urology		2,743		2,815		5,558
Neonatal		1,336		312		1,648
Blood Pressure Monitoring and Accessories		2,656		1,464		4,120
Total	$	7,749	$	4,823	$	12,572

Global 9M 2021 revenues (USD) by product category:

		Domestic		Outside US		Total
Obstetrics	$	2,864	$	559	$	3,423
Gynecology/Electrosurgery/Urology		8,229		8,130		16,359
Neonatal		3,813		1,064		4,877
Blood Pressure Monitoring and Accessories		7,649		3,832		11,481
Total	$	22,555	$	13,585	$	36,140

XML 25 R14.htm IDEA: XBRL DOCUMENT

CSI Distribution Agreement Purchase Disclosure

9 Months Ended

Sep. 30, 2021

Notes

CSI Distribution Agreement Purchase Disclosure

XML 26 R15.htm IDEA: XBRL DOCUMENT

Earnings Per Share

9 Months Ended

Sep. 30, 2021

Notes

Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:

(in thousands)	Three months ended		Nine months ended
	September 30,		September 30,
	2021	2020	2021	2020
Numerator
Net income	4,206	2,933	10,656	7,386

Denominator
Weighted average shares, basic	3,647	3,642	3,645	3,664
Dilutive effect of stock options	11	11	11	14
Diluted shares	3,658	3,653	3,656	3,678

Earnings per share, basic	1.15	0.81	2.92	2.02
Earnings per share, diluted	1.15	0.80	2.91	2.01

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2021
Notes
Subsequent Events	(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)	9 Months Ended
	Sep. 30, 2021
Policies
New Accounting Pronouncements, Policy	The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Inventories: Schedule of Inventory, Current (Tables)

9 Months Ended

Sep. 30, 2021

Tables/Schedules

Schedule of Inventory, Current

		September 30, 2021		December 31, 2020
Finished goods	$	1,436	$	1,363
Work-in-process		1,459		1,375
Raw materials		3,404		3,484
Total	$	6,299	$	6,222

XML 30 R19.htm IDEA: XBRL DOCUMENT

Revenue Recognition: Schedule Of Revenues By Product Category (Tables)

9 Months Ended

Sep. 30, 2021

Tables/Schedules

Schedule Of Revenues By Product Category

		Domestic		Outside US		Total
Obstetrics	$	1,014	$	232	$	1,246
Gynecology/Electrosurgery/Urology		2,743		2,815		5,558
Neonatal		1,336		312		1,648
Blood Pressure Monitoring and Accessories		2,656		1,464		4,120
Total	$	7,749	$	4,823	$	12,572

Global 9M 2021 revenues (USD) by product category:

		Domestic		Outside US		Total
Obstetrics	$	2,864	$	559	$	3,423
Gynecology/Electrosurgery/Urology		8,229		8,130		16,359
Neonatal		3,813		1,064		4,877
Blood Pressure Monitoring and Accessories		7,649		3,832		11,481
Total	$	22,555	$	13,585	$	36,140

XML 31 R20.htm IDEA: XBRL DOCUMENT

Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)

9 Months Ended

Sep. 30, 2021

Tables/Schedules

Schedule of Earnings Per Share, Basic and Diluted

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:

(in thousands)	Three months ended		Nine months ended
	September 30,		September 30,
	2021	2020	2021	2020
Numerator
Net income	4,206	2,933	10,656	7,386

Denominator
Weighted average shares, basic	3,647	3,642	3,645	3,664
Dilutive effect of stock options	11	11	11	14
Diluted shares	3,658	3,653	3,656	3,678

Earnings per share, basic	1.15	0.81	2.92	2.02
Earnings per share, diluted	1.15	0.80	2.91	2.01

XML 32 R21.htm IDEA: XBRL DOCUMENT

Inventories: Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Details
Finished goods	$ 1,436	$ 1,363
Work-in-process	1,459	1,375
Raw materials	3,404	3,484
Total	$ 6,299	$ 6,222

XML 33 R22.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Details
Allocated Share-based Compensation Expense	$ 41	$ 49	$ 123	$ 121

XML 34 R23.htm IDEA: XBRL DOCUMENT

Warranty Reserve (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Details
Standard and Extended Product Warranty Accrual	$ 0	$ 0

XML 35 R24.htm IDEA: XBRL DOCUMENT

Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Sales, net	$ 12,572	$ 10,479	$ 36,140	$ 30,168
Obstetrics
Sales, net	1,246		3,423
Gynecology/Electrosurgery/Urology
Sales, net	5,558		16,359
Neonatal
Sales, net	1,648		4,877
Blood Pressure Monitoring and Accessories
Sales, net	4,120		11,481
DomesticUsMember
Sales, net	7,749		22,555
DomesticUsMember \| Obstetrics
Sales, net	1,014		2,864
DomesticUsMember \| Gynecology/Electrosurgery/Urology
Sales, net	2,743		8,229
DomesticUsMember \| Neonatal
Sales, net	1,336		3,813
DomesticUsMember \| Blood Pressure Monitoring and Accessories
Sales, net	2,656		7,649
OutsideUsMember
Sales, net	4,823		13,585
OutsideUsMember \| Obstetrics
Sales, net	232		559
OutsideUsMember \| Gynecology/Electrosurgery/Urology
Sales, net	2,815		8,130
OutsideUsMember \| Neonatal
Sales, net	312		1,064
OutsideUsMember \| Blood Pressure Monitoring and Accessories
Sales, net	$ 1,464		$ 3,832

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc $ in Thousands		3 Months Ended
	Sep. 30, 2021	Mar. 31, 2019 USD ($)
Finite-lived Intangible Assets Acquired		$ 21,000
Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System	2.08

XML 37 R26.htm IDEA: XBRL DOCUMENT

Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Details
Net income	$ 4,206	$ 2,933	$ 10,656	$ 7,386
Weighted average shares, basic	3,647	3,642	3,645	3,664
Dilutive effect of stock options	11	11	11	14
Diluted shares	3,658	3,653	3,656	3,678
Earnings per share, basic	$ 1.15	$ 0.81	$ 2.92	$ 2.02
Earnings per share, diluted	$ 1.15	$ 0.80	$ 2.91	$ 2.01

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 81 198 1 false 11 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Sheet http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical Sheet http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical Statements 3 false false R4.htm 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME Sheet http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME Statements 4 false false R5.htm 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical Sheet http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical Statements 5 false false R6.htm 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Sheet http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Statements 7 false false R8.htm 000080 - Disclosure - Basis of Presentation Sheet http://www.utahmed.com/20210930/role/idr_DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles Sheet http://www.utahmed.com/20210930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples New Accounting Pronouncements and Changes in Accounting Principles Notes 9 false false R10.htm 000100 - Disclosure - Inventories Sheet http://www.utahmed.com/20210930/role/idr_DisclosureInventories Inventories Notes 10 false false R11.htm 000110 - Disclosure - Stock-Based Compensation Sheet http://www.utahmed.com/20210930/role/idr_DisclosureStockBasedCompensation Stock-Based Compensation Notes 11 false false R12.htm 000120 - Disclosure - Warranty Reserve Sheet http://www.utahmed.com/20210930/role/idr_DisclosureWarrantyReserve Warranty Reserve Notes 12 false false R13.htm 000130 - Disclosure - Revenue Recognition Sheet http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognition Revenue Recognition Notes 13 false false R14.htm 000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure Sheet http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure CSI Distribution Agreement Purchase Disclosure Notes 14 false false R15.htm 000150 - Disclosure - Earnings Per Share Sheet http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShare Earnings Per Share Notes 15 false false R16.htm 000160 - Disclosure - Subsequent Events Sheet http://www.utahmed.com/20210930/role/idr_DisclosureSubsequentEvents Subsequent Events Notes 16 false false R17.htm 000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Policies http://www.utahmed.com/20210930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples 17 false false R18.htm 000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables Inventories: Schedule of Inventory, Current (Tables) Tables 18 false false R19.htm 000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables Revenue Recognition: Schedule Of Revenues By Product Category (Tables) Tables 19 false false R20.htm 000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables) Tables 20 false false R21.htm 000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails Inventories: Schedule of Inventory, Current (Details) Details http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables 21 false false R22.htm 000220 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.utahmed.com/20210930/role/idr_DisclosureStockBasedCompensation 22 false false R23.htm 000230 - Disclosure - Warranty Reserve (Details) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureWarrantyReserveDetails Warranty Reserve (Details) Details http://www.utahmed.com/20210930/role/idr_DisclosureWarrantyReserve 23 false false R24.htm 000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails Revenue Recognition: Schedule Of Revenues By Product Category (Details) Details http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables 24 false false R25.htm 000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails CSI Distribution Agreement Purchase Disclosure (Details) Details http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure 25 false false R26.htm 000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) Details http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables 26 false false All Reports Book All Reports utmd-20210930.htm utmd-20210930.xsd utmd-20210930_cal.xml utmd-20210930_def.xml utmd-20210930_lab.xml utmd-20210930_pre.xml utmd_ex31z1.htm utmd_ex31z2.htm utmd_ex32z1.htm utmd_ex32z2.htm http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 43 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "utmd-20210930.htm": { "axisCustom": 1, "axisStandard": 3, "contextCount": 81, "dts": { "calculationLink": { "local": [ "utmd-20210930_cal.xml" ] }, "definitionLink": { "local": [ "utmd-20210930_def.xml" ] }, "inline": { "local": [ "utmd-20210930.htm" ] }, "labelLink": { "local": [ "utmd-20210930_lab.xml" ] }, "presentationLink": { "local": [ "utmd-20210930_pre.xml" ] }, "schema": { "local": [ "utmd-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 175, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 6, "total": 6 }, "keyCustom": 3, "keyStandard": 195, "memberCustom": 7, "memberStandard": 4, "nsprefix": "fil", "nsuri": "http://www.utahmed.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010 - Document - Document and Entity Information", "role": "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000100 - Disclosure - Inventories", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000110 - Disclosure - Stock-Based Compensation", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000120 - Disclosure - Warranty Reserve", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureWarrantyReserve", "shortName": "Warranty Reserve", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000130 - Disclosure - Revenue Recognition", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure", "shortName": "CSI Distribution Agreement Purchase Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000150 - Disclosure - Earnings Per Share", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000160 - Disclosure - Subsequent Events", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies", "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables", "shortName": "Inventories: Schedule of Inventory, Current (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables", "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET", "role": "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables", "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails", "shortName": "Inventories: Schedule of Inventory, Current (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000220 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureStockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:ProductWarrantyAccrual", "p", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000230 - Disclosure - Warranty Reserve (Details)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureWarrantyReserveDetails", "shortName": "Warranty Reserve (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ProductWarrantyAccrual", "p", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fil:ScheduleOfRevenuesByProductCategoryTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3_ProductOrService-Obstetrics", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails", "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "UsdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical", "role": "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E21Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "UsdPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME", "role": "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical", "role": "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "Y21Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E19_StEqComps-CommonStock", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY", "role": "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "E19_StEqComps-CommonStock", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW", "role": "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow", "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000080 - Disclosure - Basis of Presentation", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles", "role": "http://www.utahmed.com/20210930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples", "shortName": "New Accounting Pronouncements and Changes in Accounting Principles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utmd-20210930.htm", "contextRef": "D210101_210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 11, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Voluntary filer" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "fil_BloodPressureMonitoringAndAccessoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.", "label": "Blood Pressure Monitoring and Accessories" } } }, "localname": "BloodPressureMonitoringAndAccessoriesMember", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.", "label": "Common stock received and retired upon exercise of stock options" } } }, "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.", "label": "Common stock received and retired upon exercise of stock options, shares" } } }, "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fil_CoopersurgicalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the CooperSurgical Inc, during the indicated time period.", "label": "CooperSurgical Inc" } } }, "localname": "CoopersurgicalIncMember", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_DistributionRightsAcquisitionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period.", "label": "Distribution Rights Acquisition [Axis]" } } }, "localname": "DistributionRightsAcquisitionAxis", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "stringItemType" }, "fil_DistributionRightsAcquisitionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period.", "label": "Distribution Rights Acquisition" } } }, "localname": "DistributionRightsAcquisitionDomain", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_DomesticUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the DomesticUsMember, during the indicated time period.", "label": "DomesticUsMember" } } }, "localname": "DomesticUsMember", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_GynecologyElectrosurgeryUrologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.", "label": "Gynecology/Electrosurgery/Urology" } } }, "localname": "GynecologyElectrosurgeryUrologyMember", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_NeonatalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Neonatal, during the indicated time period.", "label": "Neonatal" } } }, "localname": "NeonatalMember", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_ObstetricsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Obstetrics, during the indicated time period.", "label": "Obstetrics" } } }, "localname": "ObstetricsMember", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right of Use Asset Amortization.", "label": "Amortization of Right of Use Assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "fil_OutsideUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the OutsideUsMember, during the indicated time period.", "label": "OutsideUsMember" } } }, "localname": "OutsideUsMember", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.", "label": "Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System" } } }, "localname": "RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "decimalItemType" }, "fil_ScheduleOfRevenuesByProductCategoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.", "label": "Schedule Of Revenues By Product Category" } } }, "localname": "ScheduleOfRevenuesByProductCategoryTextBlock", "nsuri": "http://www.utahmed.com/20210930", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" ], "xbrltype": "textBlockItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r119", "r164", "r165", "r237", "r260", "r261" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r119", "r164", "r165", "r237", "r260", "r261" ], "lang": { "en-us": { "role": { "label": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r120", "r121", "r164", "r166", "r262", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "label": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r120", "r121", "r164", "r166", "r262", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26", "r233" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r7", "r15", "r123", "r124" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts & other receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": { "auth_ref": [], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).", "label": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r72", "r73", "r74", "r174", "r175", "r176", "r212" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r63", "r141" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.", "label": "Total adjustments", "totalLabel": "Total adjustments" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r171", "r173", "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r69", "r108", "r111", "r117", "r128", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r201", "r205", "r215", "r231", "r233", "r244", "r252" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r36", "r69", "r128", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r201", "r205", "r215", "r231", "r233" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r25", "r65" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash & investments", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r59", "r220" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net increase in cash and cash equivalents", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r72", "r73", "r212" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r233" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2021, 3,649 shares and December 31, 2020, 3,643 shares" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r40", "r42", "r43", "r48", "r248", "r256" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Total comprehensive income", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r52", "r237" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r63", "r70", "r187", "r194", "r195", "r196" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes {1}", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r182", "r183" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": { "auth_ref": [], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 8.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.", "label": "Tax benefit attributable to exercise of stock options" } } }, "localname": "DeferredTaxExpenseFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r185", "r186" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred tax liability - Femcare IIA" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r63", "r144" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Common stock dividends", "negatedLabel": "Common stock dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r49", "r81", "r82", "r83", "r84", "r85", "r92", "r94", "r95", "r96", "r97", "r101", "r102", "r213", "r214", "r249", "r257" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings per share, basic", "verboseLabel": "Earnings per common share (basic)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r49", "r81", "r82", "r83", "r84", "r85", "r94", "r95", "r96", "r97", "r101", "r102", "r213", "r214", "r249", "r257" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings per share, diluted", "verboseLabel": "Earnings per common share (diluted)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r98", "r99", "r100", "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r220" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r44", "r45", "r46", "r72", "r73", "r74", "r78", "r86", "r88", "r104", "r129", "r161", "r162", "r174", "r175", "r176", "r188", "r189", "r212", "r221", "r222", "r223", "r224", "r225", "r227", "r263", "r264", "r265", "r289" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r140" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Other intangible assets - accumulated amortization", "negatedLabel": "Other intangible assets - accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r140", "r241" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Other intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r63", "r143", "r146" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "(Gain) loss on disposal of assets", "negatedLabel": "(Gain) loss on disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r135", "r136", "r233", "r243" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r51", "r69", "r108", "r110", "r113", "r116", "r118", "r128", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r215" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r47", "r108", "r110", "r113", "r116", "r118", "r242", "r247", "r250", "r258" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r87", "r88", "r107", "r184", "r193", "r197", "r259" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r60", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r62" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 12.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts payable {1}", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r62" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 9.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Accounts receivable and other receivables", "negatedLabel": "Accounts receivable and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r62" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 13.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses {1}", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r62" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 10.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Inventories {1}", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r62" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 11.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Prepaid expenses and other current assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "CSI Distribution Agreement Purchase Disclosure" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r137", "r139" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Other intangible assets, net", "totalLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Cash paid during the period for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventories {2}", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r21", "r133" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r34", "r233" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r33" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r32" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r69", "r112", "r128", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r202", "r205", "r206", "r215", "r231", "r232" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r69", "r128", "r215", "r233", "r245", "r254" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total liabilities and stockholders' equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29", "r69", "r128", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r202", "r205", "r206", "r215", "r231", "r232", "r233" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Total current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r59" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash used in financing activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r59" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash used in investing activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r59", "r61", "r64" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash provided by operating activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r2", "r75", "r76", "r79", "r80", "r89", "r90", "r91", "r126", "r127", "r130", "r131", "r167", "r168", "r169", "r170", "r177", "r190", "r191", "r192", "r211", "r216", "r217", "r218", "r230", "r238", "r239", "r240", "r266", "r267", "r268", "r269", "r270", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "New Accounting Pronouncements and Changes in Accounting Principles" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r108", "r110", "r113", "r116", "r118" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating income", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r229" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r228" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease - right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r35", "r233" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r37" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r37", "r38", "r219", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r57" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Common stock purchased and retired {1}", "negatedLabel": "Common stock purchased and retired" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r57" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payment of dividends", "negatedLabel": "Payment of dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r55" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Property and equipment", "negatedLabel": "Property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r56" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock - options" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r147", "r148", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureWarrantyReserveDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Warranty Reserve" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureWarrantyReserve" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r39", "r41", "r46", "r58", "r69", "r77", "r87", "r88", "r108", "r110", "r113", "r116", "r118", "r128", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r200", "r203", "r204", "r208", "r209", "r214", "r215", "r250" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r145", "r233", "r251", "r255" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r50", "r132" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for (recovery of) losses on accounts receivable" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r181", "r236", "r281" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research & development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r162", "r178", "r233", "r253", "r266", "r270" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r72", "r73", "r74", "r78", "r86", "r88", "r129", "r174", "r175", "r176", "r188", "r189", "r212", "r263", "r265" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r105", "r106", "r109", "r114", "r115", "r119", "r120", "r122", "r163", "r164", "r237" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Sales, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r22", "r23", "r24" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r62" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Equity Balance, shares", "periodEndLabel": "Equity Balance, shares", "periodStartLabel": "Equity Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r31", "r44", "r45", "r46", "r72", "r73", "r74", "r78", "r86", "r88", "r104", "r129", "r161", "r162", "r174", "r175", "r176", "r188", "r189", "r212", "r221", "r222", "r223", "r224", "r225", "r227", "r263", "r264", "r265", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails", "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r72", "r73", "r74", "r104", "r237" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails", "http://www.utahmed.com/20210930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r161", "r162", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued upon exercise of employee stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r31", "r161", "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued upon exercise of employee stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock option compensation expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r13", "r14", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Common stock purchased and retired, shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r13", "r14", "r161", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Common stock purchased and retired" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r69", "r125", "r128", "r215", "r233" ], "calculation": { "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total stockholders' equity", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r45", "r69", "r72", "r73", "r74", "r78", "r86", "r128", "r129", "r162", "r174", "r175", "r176", "r188", "r189", "r198", "r199", "r207", "r212", "r215", "r221", "r222", "r227", "r264", "r265", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Equity Balance, value", "periodEndLabel": "Equity Balance, value", "periodStartLabel": "Equity Balance, value" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tables/Schedules" } } }, "localname": "TableTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive effect of stock options" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r93", "r97" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted shares", "verboseLabel": "Shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r92", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares, basic", "verboseLabel": "Shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.utahmed.com/20210930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.utahmed.com/20210930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r282": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r283": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r284": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r285": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r286": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r287": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r288": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" } }, "version": "2.1" } ZIP 44 0001811884-21-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001811884-21-000016-xbrl.zip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end